The Centers for Disease Control and Prevention Sept. 22 recommended the first maternal vaccine to protect newborns from severe illness from respiratory syncytial virus, the leading cause of hospitalization for U.S. infants. In a clinical study, the Pfizer vaccine (Abrysvo) reduced the risk of hospitalization by 57% in the first six months after birth. CDC recommends receiving one dose of the vaccine during weeks 32-36 of pregnancy.

“I encourage parents to talk to their doctors about how to protect their little ones against serious RSV illness, using either a vaccine given during pregnancy, or an RSV immunization given to your baby after birth,” said CDC Director Mandy Cohen, M.D.

The Food and Drug Administration approved the vaccine in August. It is currently available in some U.S. locations and should become more available in the coming weeks, CDC said.

Related News Articles

Headline
Nearly 57% of mothers did not attend a postpartum follow-up visit three to eight weeks after giving birth, according to a report published July 29 by Cedar…
Headline
The Senate Appropriations Committee July 31 advanced the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services,…
Headline
The Joint Commission July 29 announced an initiative to address “gaps” in how children’s hospitals are accredited and certified. The program will remove or…
Headline
The AHA July 24 announced it is collaborating with health care technology leader Epic to help hospitals adopt tools that support the early detection and…
Headline
A Health Affairs study on the decline of obstetric services in rural and urban hospitals nationwide from 2010-2022 found that seven states had at least 25% of…
Headline
The latest video in the AHA’s series “Medicaid: Real Lives, Real Care” features Melissa Fannon-Wisner, DNP, nurse educator and nurse practitioner at Valley…